Fundraising FoxRDiscovery — Full Portfolio
11 tracked investments · listed companies and verified rows first
Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.
BiotechDeep TechLongevityPalo Alto, US
Amy Wang(PhD)inKenneth Horne(Executive Officer, Director)inDylan Morris(Director)inCristina Ghenoiu(Director)in
BoardTaro Inaba(Director)in
Co-investorsRemiges Ventures, Inc.Insight PartnersRA CapitalAN Venture Partners
Imel Biotherapeutics is a biotech company focused on mitochondrial biology, targeting mitochondrial dysfunction implicated in aging, cellular senescence, and T cell exhaustion in the elderly population.
BiotechLongevity
Co-investorsPontifax Venture Capital
NapaJen Pharma is a biopharmaceutical research and development company developing nucleic acid (oligonucleotide) drugs using a proprietary cell-specific drug delivery platform that enables delivery to immune cells for precision-targeted immunosuppression and controlled immuno-stimulation.
BiotechDeep TechMedical DevicesSeattle, US
Hironori (Randy) Ando(Founder)in有馬賢治(CEO & Director (NapaJen Pharma, Inc.); Representative Director (NapaJen Pharma K.K.))
Co-investorsRemiges Ventures, Inc.
Myrodia Therapeutics is a Japanese biopharmaceutical company developing drug candidates based on its "sensory drug discovery" concept, which uses sensory stimuli to induce artificial hibernation and protective physiological states.
BiotechDeep TechHealthtech
小早川 高(CSO / Founder)小早川 令子(Founder)神谷 勇輝(CEO / 代表取締役)水野 敦之(CFO)小林 実(COO)
Co-investorsRemiges Ventures, Inc.ANRI
Sanodyne Therapeutics develops SNT-001, an orally administered small-molecule compound intended to treat peripheral neuropathy and neuropathic pain.
BiotechDeep Tech
Co-investorsJIC Venture Growth Investments
Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease.
BiotechDeep TechHealthtechSan Francisco Bay Area, US
Kousaku Ohinata, Ph.D.(Founder, Scientific Advisor)Titus Plattel(CEO & President)inBrian Rogers(Leadership Team)inNeil Schwartz(Leadership Team)inSujata Sankar(Leadership Team)inSteven King(Leadership Team)in
Co-investorsKyoto University Innovation CapitalMiyako CapitalRemiges Ventures, Inc.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Pattern Pharma Inc.IMELMyrodiaSanodyne TherapeuticsViage Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.